NCT03089827Enrolling by invitation
Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
Participants enrolled at the Alzheimer's Disease Research Center (ADRC) at Wake Forest School of Medicine will be invited to take part in this study. The purpose of this study is to identify and measure the amount of a protein called amyloid in the brain.It is thought that the build up of amyloid may be related to the development of Alzheimer's disease.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 17 Mar 2017
- Start date
- 21 May 2014
- Primary completion date
- Apr 2030
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Alzheimer disease
- NCT number
- NCT03089827
What you commit to
- Study type: Observational
- Planned participants: 800
- From 21 May 2014 to the primary completion date, Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Enrolled in a study with the Alzheimer's Disease Research Center.
Age in the registry: 55 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wake Forest Baptist Medical Center Coordinator of this site? Confirm its status | Winston-Salem | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.